Tim Casey

Exemestane versus Tamoxifen for Women with Premenopausal Breast Cancer

11/03/2014

After a median follow-up of 5.7 years, an analysis found that premenopausal women with HR+ early breast cancer who received exemestane plus ovarian function suppression had a significant improvement in disease-free survival.

After a median follow-up of 5.7...

11/03/2014

First Report Managed Care

News

Assessing New Treatment Options for MS

05/21/2014

Tim Casey ;

Since 2010, the FDA has approved 3 oral drugs—fingolimod, teriflunomide, and dimethyl fumarate—to treat patients with multiple sclerosis (MS).

Since 2010, the FDA has approved...

05/21/2014

First Report Managed Care

Bleeding Events in Patients with VTE in a Real World Setting

01/20/2014

Tim Casey ;

New Orleans—A retrospective observational analysis of a commercial insurance and Medicare database found that among patients with venous thromboembolism (VTE), the annual incidence of major bleeding was 3.9% and the annual incidence of...

New Orleans—A retrospective...

01/20/2014

First Report Managed Care

Management Strategies for Obese Patients with Type 2 Diabetes

08/14/2013

Tim Casey ;

A trial of obese patients with type 2 diabetes found that Roux-en-Y gastric bypass surgery had greater weight loss than management programs.

A trial of obese patients with...

08/14/2013

First Report Managed Care

Value-Based Benefit Design Increases Adherence and Lowers Costs

03/19/2013

Tim Casey ;

Las Vegas—In 2009, pharmacy spending accounted for 16% of Whirlpool Corporation’s healthcare spending. Of the 22,000 employees, an increasing number had chronic conditions, including diabetes, coronary artery disease, and asthma. Stacy White,...

Las Vegas—In 2009, pharmacy...

03/19/2013

First Report Managed Care

Vascepa™, an Omega-3 Fatty Acid, for Patients with Severe Hypertriglyceridemia

11/27/2012

Tim Casey ;

Cincinnati—Approximately 4 million people in the United States have severe hypertriglyceridemia, which has been associated with heart disease, stroke, and other conditions. The effects are intensified in people with low high-density...

Cincinnati—Approximately 4...

11/27/2012

First Report Managed Care

Insulin Glargine Has Neutral Effect on CV Outcomes and Cancers

08/16/2012

Tim Casey ;

Philadelphia—After >6 years of follow-up, a large, international, randomized trial found that daily injections of insulin glargine in patients with type 2 diabetes, or with a high risk of the disease, had a neutral effect on cancers,...

Philadelphia—After >6 years...

08/16/2012

First Report Managed Care

State Officials Discuss Medicaid Programs

04/25/2012

Tim Casey ;

State Medicaid officials discussed issues they face balancing difficult economic conditions and offered insights into how they will deal with potential problems.

State Medicaid officials...

04/25/2012

First Report Managed Care

Type 2 Diabetes Treatment Options Increasing

12/14/2011

Tim Casey ;

Las Vegas—Until the past decade, patients with type 2 diabetes had few treatment options. They were limited to animal insulin, sulfonylurea, or metformin. The US Food and Drug Administration (FDA) approved metformin in 1994; it is used in...

Las Vegas—Until the past decade,...

12/14/2011

First Report Managed Care

Maintenance Therapy with Pemetrexed Improves Progression-Free Survival in Advanced Lung Cancer

08/22/2011

Tim Casey ;

Chicago—A randomized, double-blind, placebo-controlled phase 3 trial found that patients with advanced nonsquamous non–small-cell lung cancer (NSCLC) taking pemetrexed continuation maintenance therapy had a significantly improved...

Chicago—A randomized,...

08/22/2011

First Report Managed Care